Cited by 1,273CRISPR and Genetic EngineeringRNA regulation and diseaseRNA Interference and Gene Delivery

The DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering

Open access

Zhang, Xiao-Hui, Tee, Louis Y, Wang, Xiao-Gang, Huang, Qun-Shan, Yang, Shi-Hua·2015·Molecular Therapy - Nucleic Acids

DOI 10.1038/mtna.2015.37PMC PMC4877446

Open this paper in CoChat — free account Open PDF

Abstract

CRISPR/Cas9 is a versatile genome-editing technology that is widely used for studying the functionality of genetic elements, creating genetically modified organisms as well as preclinical research of genetic disorders. However, the high frequency of off-target activity (≥50%)-RGEN (RNA-guided endonuclease)-induced mutations at sites other than the intended on-target site-is one major concern, especially for therapeutic and clinical applications. Here, we review the basic mechanisms underlying off-target cutting in the CRISPR/Cas9 system, methods for detecting off-target mutations, and strategies for minimizing off-target cleavage. The improvement off-target specificity in the CRISPR/Cas9 system will provide solid genotype-phenotype correlations, and thus enable faithful interpretation of genome-editing data, which will certainly facilitate the basic and clinical application of this technology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/mtna.2015.37

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741

Flagged first, then by citations

Show all 82 references

1 of the 82 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 1,000

Searching for Potential gRNA Off-Target Sites for CRISPR/Cas9 Using Automata Processing Across Different Platforms
Bo, C., Dang, V., Sadredini, E., & Kevin Skadron, Y. (2018) · IEEE International Symposium on High-Performance Computer Architecture (HPCA) · doi:10.1109/hpca.2018.00068 · Cited by 32
Genome-Wide Off-Target Analysis in CRISPR-Cas9 Modified Mice and Their Offspring
Yan, D., Li, H., Zhao, L., Koopman, P. A., Zhang, F., & Huang, J. X. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400503 · Cited by 35
Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies
Nguyen, Q., Lim, K. R. Q., & Yokota, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030733 · Cited by 33
Elimination of blaKPC−2-mediated carbapenem resistance in Escherichia coli by CRISPR-Cas9 system
Tao, S., Chen, H., Li, N., Fang, Y., Zhang, H., Yao, X., Chen, L., & Liang, W. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03058-7 · Cited by 31
HMGA2 promotes cancer metastasis by regulating epithelial–mesenchymal transition
Ma, Q., Ye, S., Liu, H., Zhao, Y., Mao, Y., & Zhang, W. Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1320887 · Cited by 32
Efficient and Heritable Targeted Mutagenesis in Mosses Using the CRISPR/Cas9 System
Nomura, T., Sakurai, T., Osakabe, Y., Osakabe, K., & Sakakibara, H. (2016) · Plant and Cell Physiology · doi:10.1093/pcp/pcw173 · Cited by 31
Cre/lox-Recombinase-Mediated Cassette Exchange for Reversible Site-Specific Genomic Targeting of the Disease Vector, Aedes aegypti
Häcker, I., Harrell, R. A., Eichner, G., Pilitt, K. L., O’Brochta, D. A., Handler, A. M., & Schetelig, M. F. (2017) · Scientific Reports · doi:10.1038/srep43883 · Cited by 31
Evaluating the probability of CRISPR‐based gene drive contaminating another species
Courtier‐Orgogozo, V., Danchin, A., Gouyon, P., & Boëte, C. (2020) · Evolutionary Applications · doi:10.1111/eva.12939 · Cited by 33
Targeted RNA editing: novel tools to study post-transcriptional regulation
Xu, W., Biswas, J., Singer, R. H., & Rosbash, M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.10.010 · Cited by 31
Applications of CRISPR/Cas gene-editing technology in yeast and fungi
Liao, B., Chen, X., Zhou, X., Zhou, Y., Shi, Y., Ye, X., Liao, M., Zhou, Z., Cheng, L., & Ren, B. (2021) · Archives of Microbiology · doi:10.1007/s00203-021-02723-7 · Cited by 34
Inducible CRISPR genome-editing tool: classifications and future trends
Dai, X., Chen, X., Fang, Q., Li, J., & Bai, Z. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1378999 · Cited by 32
Rapid and highly efficient genomic engineering with a novel iEditing device for programming versatile extracellular electron transfer of electroactive bacteria
Fan, Y., Tang, Q., Li, Y., Li, F., Wu, J., Li, W., & Yu, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15374 · Cited by 31
Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment
Zhou, S., Li, Y., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70 · Cited by 30
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 32
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
An analysis of possible off target effects following CAS9/CRISPR targeted deletions of neuropeptide gene enhancers from the mouse genome
Hay, E. A., Khalaf, A. R., Marini, P., Brown, A., Heath, K., Sheppard, D., & MacKenzie, A. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.11.003 · Cited by 31
An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue
Jin, J., Xu, Y., Huo, L., Ma, L., Scott, A. W., Pizzi, M. P., Li, Y., Wang, Y., Yao, X., Song, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228910 · Cited by 31
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Nezhad, M. S., Yazdanifar, M., Abdollahpour‐Alitappeh, M., Sattari, A., Seifalian, A. M., & Bagheri, N. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27882 · Cited by 30
CRISPR/Cas 9-Based Editing in the Production of Bioactive Molecules
Bhagwat, A. C., Patil, A. M., & Saroj, S. D. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00418-4 · Cited by 30
CRISPR/Cas9—A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects
Ahmad, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911482 · Cited by 30
N-Glycolylneuraminic Acid (Neu5Gc) Null Large Animals by Targeting the CMP-Neu5Gc Hydroxylase (CMAH)
Perota, A., & Galli, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02396 · Cited by 30
Medical applications of clustered regularly interspaced short palindromic repeats (CRISPR/Cas) tool: A comprehensive overview
Araldi, R. P., Khalil, C., Grignet, P. H., Teixeira, M. R., de Melo, T. C., Módolo, D. G., Fernandes, L. G. V., Ruiz, J. L. M., & de Souza, E. B. (2020) · Gene · doi:10.1016/j.gene.2020.144636 · Cited by 33
State of the Art and Perspectives of Gene Therapy in Heart Failure. A Scientific Statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases
Linthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 29
Intranasal delivery of extracellular vesicles: A promising new approach for treating neurological and respiratory disorders
Sánchez, S. V., Otavalo, G. N., Gazeau, F., Silva, A., & Morales, J. O. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.018 · Cited by 31
Exploring CRISPR-Cas: The transformative impact of gene editing in molecular biology
Pandey, V. P., Sharma, S., & Pokharel, Y. R. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102717 · Cited by 29
Use of Human Pluripotent Stem Cell-Derived Cells for Neurodegenerative Disease Modeling and Drug Screening Platform
García‐León, J. A., Vitórica, J., & Gutiérrez, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0520 · Cited by 30
CRISPR Diagnosis and Therapeutics with Single Base Pair Precision
Lee, S. H., Park, Y., Jin, Y. B., Kim, S., & Hur, J. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.008 · Cited by 29
CRISPR/Cas9-Mediated Transgenesis of the Masu Salmon (Oncorhynchus masou) elovl2 Gene Improves n-3 Fatty Acid Content in Channel Catfish (Ictalurus punctatus)
Xing, D., Su, B., Li, S., Bangs, M. R., Creamer, D., Coogan, M. P., Wang, J., Simora, R. M. C., Ma, X., Hettiarachchi, D. U., et al. (2022) · Marine Biotechnology · doi:10.1007/s10126-022-10110-6 · Cited by 29
Synergy of nanocarriers with CRISPR-Cas9 in an emerging technology platform for biomedical appliances: Current insights and perspectives
Bhattacharjee, R., Jana, A., Nandi, A., Sinha, A., Bhattacharjee, A., Mitra, S., Kar, S., Dey, A., Singh, S. K., Varma, R. S., et al. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.111415 · Cited by 29
Interpretable CRISPR/Cas9 off-target activities with mismatches and indels prediction using BERT
Luo, Y., Chen, Y., Xie, H., Zhu, W., & Zhang, G. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.107932 · Cited by 30
Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells
Yamashita, N., Saito, N., Zhao, S., Terai, K., Hiruta, N., Park, Y., Bujo, H., Nemoto, K., & Kanno, Y. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.02.033 · Cited by 29
Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research
Eun, K., Park, M. G., Jeong, Y. W., Jeong, Y. I., Hyun, S., Hwang, W. S., Kim, S.-H., & Kim, H. (2019) · BMC Biotechnology · doi:10.1186/s12896-018-0491-5 · Cited by 30
CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
Zhang, X., Wang, L., Liu, M., & Li, D. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9057-2 · Cited by 28
Self-citation
Advances in Chimeric Antigen Receptor T‐Cell Therapies for Solid Tumors
Baybutt, T. R., Flickinger, J. C., Caparosa, E. M., & Snook, A. E. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1280 · Cited by 28
CRISPR-Cas9 in agriculture: Approaches, applications, future perspectives, and associated challenges
Adhikari, P., & Poudel, M. (2020) · Malaysian Journal of Halal Research · doi:10.2478/mjhr-2020-0002 · Cited by 23
Effects of electroporation treatment using different concentrations of Cas9 protein with gRNA targeting Myostatin (MSTN) genes on the development and gene editing of porcine zygotes
Le, Q. A., Hirata, M., Nguyen, N. T., Takebayashi, K., Wittayarat, M., Sato, Y., Namula, Z., Nii, M., Tanihara, F., & Otoi, T. (2020) · Animal Science Journal · doi:10.1111/asj.13386 · Cited by 28
A Transposon-Associated CRISPR/Cas9 System Specifically Eliminates both Chromosomal and Plasmid-Borne mcr-1 in Escherichia coli
He, Y., Yan, J.-R., He, B., Ren, H., Kuang, X., Long, T., Chen, C., Liao, X., Liu, Y., & Sun, J. G. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01054-21 · Cited by 28
Novel Thrombotic Function of a Human SNP in STXBP5 Revealed by CRISPR/Cas9 Gene Editing in Mice
Zhu, Q. M., Ko, K. A., Ture, S. K., Mastrangelo, M. A., Chen, M., Johnson, A. D., O’Donnell, C. J., Morrell, C. N., Miano, J. M., & Lowenstein, C. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308614 · Cited by 27
Conditional deletion of glucocorticoid receptors in rat brain results in sex-specific deficits in fear and coping behaviors
Scheimann, J. R., Moloney, R. D., Mahbod, P., Morano, R. L., Fitzgerald, M. E., Hoskins, O., Packard, B. A., Cotella, E. M., Hu, Y., & Herman, J. P. (2019) · eLife · doi:10.7554/elife.44672 · Cited by 31
A CRISPR-Cas9 repressor for epigenetic silencing of KRAS
Liu, J., Sun, M., Cho, K. B., Gao, X., & Guo, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105304 · Cited by 28
The Role of Metabolic Engineering Technologies for the Production of Fatty Acids in Yeast
Ullah, N., Shahzad, K., & Wang, M. (2021) · Biology · doi:10.3390/biology10070632 · Cited by 27
Hypoxia-directed tumor targeting of CRISPR-Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles
Davis, A. M., Morris, K. V., & Shevchenko, G. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.008 · Cited by 27
CRISPR/Cas9 System: A Potential Tool for Genetic Improvement in Floricultural Crops
Sirohi, U., Kumar, M., Sharma, V. R., Teotia, S., Singh, D., Chaudhary, V., Priya, & Yadav, M. K. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00523-y · Cited by 28
In vitro models for head and neck cancer: Current status and future perspective
Moya‐Garcia, C. R., Okuyama, H., Sadeghi, N., Li, J., Tabrizian, M., & Li‐Jessen, N. Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960340 · Cited by 28
High-performance gene expression and knockout tools using sleeping beauty transposon system
Hu, K., Li, Y., Wu, W., Chen, H., Chen, Z., Zhang, Y., Guo, Y., & Yin, D. (2018) · Mobile DNA · doi:10.1186/s13100-018-0139-y · Cited by 27
Frequency of off-targeting in genome edited pigs produced via direct injection of the CRISPR/Cas9 system into developing embryos
Carey, K., Ryu, J., Uh, K., Lengi, A. J., Clark‐Deener, S., Corl, B. A., & Lee, K. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0517-7 · Cited by 27
In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline?
Lubroth, P., Colasante, G., & Lignani, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.632522 · Cited by 28
PINK1 gene mutation by pair truncated sgRNA/Cas9-D10A in cynomolgus monkeys
Chen, Z., 650500，中国, 昆. 昆., Wang, J.-Y., Kang, Y., Yang, Q., Gu, X.-Y., Zhi, D., Li, Y., Long, C., Shen, B., et al. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2021.023 · Cited by 27
Background-suppressed live visualization of genomic loci with an improved CRISPR system based on a split fluorophorePreprint
Chaudhary, N., Nho, S.-H., Cho, H., Gantumur, N., Ra, J. S., Myung, K., & Kim, H. (2020) · Genome Research · doi:10.1101/gr.260018.119 · Cited by 27
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads
Leandro, K., Rufino‐Ramos, D., Breyne, K., Ianni, E. D., Lopes, S., Nobre, R. J., Kleinstiver, B. P., Perdigão, P. R. L., Breakefield, X. O., & de Almeida, L. P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115346 · Cited by 27
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A., Kachanov, A., Brezgin, S., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 30
Rapid and efficient analysis of gene function using CRISPR ‐Cas9 in Xenopus tropicalis founders
Shigeta, M., Sakane, Y., Iida, M., Suzuki, M., Kashiwagi, K., Kashiwagi, A., Fujii, S., Yamamoto, T., & Suzuki, K. (2016) · Genes to Cells · doi:10.1111/gtc.12379 · Cited by 26
Development of CRISPR/Cas9-mediated gene disruption systems in Giardia lamblia
Lin, Z., Gan, S. W., Tung, S.-Y., Ho, C.-C., Su, L., & Sun, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213594 · Cited by 26
Detection of cell-type-specific risk-CpG sites in epigenome-wide association studies
Luo, X., Yang, C., & Wei, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-10864-z · Cited by 26
LEDGF/p75 Is Required for an Efficient DNA Damage Response
Liedtke, V., Schröder, C., Roggenbuck, D., Weiss, R., Stohwasser, R., Schierack, P., Rödiger, S., & Schenk, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115866 · Cited by 26
The SARS-CoV-2 SSHHPS Recognized by the Papain-like Protease
Reynolds, N. D., Aceves-Ewing, N. M., Liu, J. L., Compton, J. R., Leary, D. H., Freitas, B. T., Pegan, S. D., Doctor, K. Z., Wu, F. Y., Hu, X., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00866 · Cited by 26
Mismatch Intolerance of 5′-Truncated sgRNAs in CRISPR/Cas9 Enables Efficient Microbial Single-Base Genome Editing
Lee, H. J., Kim, H. J., & Lee, S. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126457 · Cited by 26
CRISPR/Cas9 editing of the MYO7A gene in rhesus macaque embryos to generate a primate model of Usher syndrome type 1B
Ryu, J., Statz, J. P., Chan, W. K., Burch, F. C., Brigande, J. V., Kempton, B., Porsov, E. V., Renner, L. M., McGill, T., Burwitz, B. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13689-x · Cited by 26
Unclasping potentials of genomics and gene editing in chickpea to fight climate change and global hunger threat
Singh, C., Kumar, R., Sehgal, H., Bhati, S., Singhal, T., Gayacharan, Nimmy, M. S., Yadav, R., Gupta, S. K., Abdallah, N. A., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1085024 · Cited by 26
Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency
Yılmaz, B. Ş., & Gissen, P. (2023) · Biomedicines · doi:10.3390/biomedicines11082227 · Cited by 26
CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression
Cai, H., Zhang, B., Ahrenfeldt, J., Joseph, J. V., Riedel, M., Gao, Z., Thomsen, S. K., Christensen, D. S., Bak, R. O., Hager, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46370-0 · Cited by 26
CRISPR/Cas9-Mediated Treatment Ameliorates the Phenotype of the Epidermolytic Palmoplantar Keratoderma-like Mouse
Luan, X., Chen, X., Tang, Y., Zhang, J., Gao, X., Ke, H., Lin, Z., & Zhang, X. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.005 · Cited by 28
Self-citation
Mapping and editing of nucleic acid modifications
Chen, L.-Q., Zhao, W., & Luo, G. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.010 · Cited by 26
Strategies for improving the genome-editing efficiency of class 2 CRISPR/Cas system
Wang, L., & Han, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38588 · Cited by 26
Therapeutic genome engineering via CRISPR ‐Cas systems
Moreno, A. M., & Mali, P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1380 · Cited by 25
Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection
Albers, J. J., Ammon, T., Gosmann, D., Audehm, S., Thoene, S., Winter, C., Secci, R., Wolf, A. A., Stelzl, A., Steiger, K., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900367 · Cited by 25
The protean world of non-coding RNAs in glioblastoma
Paulmurugan, R., Malhotra, M., & Massoud, T. F. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01798-6 · Cited by 25
A DNA-Free Editing Platform for Genetic Screens in Soybean via CRISPR/Cas9 Ribonucleoprotein Delivery
Subburaj, S., Zanatta, C. B., Nunn, J. A. L., Hoepers, A. M., Nodari, R. O., & Agapito-Tenfen, S. Z. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.939997 · Cited by 25
Development and applications of a CRISPR activation system for facile genetic overexpression in Candida albicans
Gervais, N. C., Bella, A. A. L., Wensing, L. F., Sharma, J., Acquaviva, V., Best, M. A., López, R. O. C., Fogal, M., Uthayakumar, D., Chavez, A., et al. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac301 · Cited by 27
Engineering Inflammation‐Resistant Cartilage: Bridging Gene Therapy and Tissue Engineering
Bonato, A., Fisch, P., Ponta, S., Fercher, D., Manninen, M. J., Weber, D. M., Eklund, K. K., Barreto, G., & Zenobi‐Wong, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202271 · Cited by 25
CRISPRimmunity: an interactive web server for CRISPR-associated Important Molecular events and Modulators Used in geNome edIting Tool identifYing
Zhou, F., Yu, X., Gan, R., Ren, K., Chen, C., Ren, C., Cui, M., Liu, Y., Gao, Y., Wang, S., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad425 · Cited by 25
Massively parallel CRISPR off-target detection enables rapid off-target prediction model building
Tian, R., Cao, C., He, D., Dong, D., Sun, L., Liu, J., Chen, Y., Wang, Y., Huang, Z., Li, L., et al. (2023) · Med · doi:10.1016/j.medj.2023.05.005 · Cited by 25
Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases
Bigini, F., Hyeon, L. S., Sun, Y. J., Sun, Y., & Mahajan, V. B. (2023) · Vision Research · doi:10.1016/j.visres.2023.108317 · Cited by 26
Bacteriophage λ exonuclease and a 5′-phosphorylated DNA guide allow PAM-independent targeting of double-stranded nucleic acids
Fu, S., Li, J., Chen, J., Zhang, L., Liu, J., Liu, H., & Su, X. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02388-9 · Cited by 25
mCAL: A New Approach for Versatile Multiplex Action of Cas9 Using One sgRNA and Loci Flanked by a Programmed Target Sequence
Finnigan, G. C., & Thorner, J. W. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.116.029801 · Cited by 26
Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy
Chen, H., Sun, T., & Jiang, C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.014 · Cited by 25
Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing
Hu, W., Kumar, A., Ahmed, S. F., Qi, S., Ma, D. K. G., Chen, H., Singh, G. J., Casan, J. M. L., Haber, M., Voskoboinik, I., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01336-0 · Cited by 24
Robust CRISPR/Cas9 Genome Editing of the HUDEP-2 Erythroid Precursor Line Using Plasmids and Single-Stranded Oligonucleotide Donors
Moir-Meyer, G., Cheong, P. L., Olijnik, A.-A., Brown, J. M., Knight, S. J. L., King, A. J., Kurita, R., Nakamura, Y., Gibbons, R. J., Higgs, D. R., et al. (2018) · Methods and Protocols · doi:10.3390/mps1030028 · Cited by 24
A quantitative risk assessment method for synthetic biology products in the environment
Rycroft, T., Hamilton, K. A., Haas, C. N., & Linkov, I. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.133940 · Cited by 24
CRISPR/Cas9-Constructed Pseudorabies Virus Mutants Reveal the Importance of UL13 in Alphaherpesvirus Escape from Genome Silencing
Cleemput, J. V., Koyuncu, O. Ö., Laval, K., Engel, E. A., & Enquist, L. W. (2020) · Journal of Virology · doi:10.1128/jvi.02286-20 · Cited by 24
Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies
Grewal, S., Smith, J. J., & Carr, A. F. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841421997191 · Cited by 24
Genome-wide specificity of plant genome editing by both CRISPR–Cas9 and TALEN
Bessoltane, N., Charlot, F., Guyon‐Debast, A., Charif, D., Mara, K., Collonnier, C., Perroud, P., Tepfer, M., & Nogué, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-13034-2 · Cited by 25
Gene-Targeted DNA Methylation: Towards Long-Lasting Reprogramming of Gene Expression?
Cortés-Mancera, F., Sarno, F., Goubert, D., & Rots, M. G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11454-0_18 · Cited by 25
Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment
Wei, Y., Zhao, Z., & Ma, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1037124 · Cited by 24
Generation of Eco-Friendly and Disease-Resistant Channel Catfish (Ictalurus punctatus) Harboring the Alligator Cathelicidin Gene via CRISPR/Cas9 Engineering
Wang, J., Su, B., Xing, D., Bruce, T. J., Li, S., Bern, L., Shang, M., Johnson, A., Simora, R. M. C., Coogan, M. P., et al. (2024) · Engineering · doi:10.1016/j.eng.2023.12.005 · Cited by 24
Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery
Romanishin, A. O., Vasilev, A., Khasanshin, E., Evtekhov, A., Pusynin, E., Rubina, K., Kakotkin, V., Agapov, M., & Semina, E. (2024) · Virology · doi:10.1016/j.virol.2024.110033 · Cited by 24
A Two-Step Method for Obtaining Highly Pure Cas9 Nuclease for Genome Editing, Biophysical, and Structural Studies
Rajagopalan, N., Kagale, S., Bhowmik, P., & Song, H. (2018) · Methods and Protocols · doi:10.3390/mps1020017 · Cited by 24
CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening
Christidi, E., Huang, H., & Brunham, L. R. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.06.002 · Cited by 24
Exploiting epigenetics for the treatment of inborn errors of metabolism
Rutten, M. G. S., Rots, M. G., & Oosterveer, M. H. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12093 · Cited by 26
Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids
Chen, K. G., Zhong, P., Zheng, W., & Beekman, J. M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.029 · Cited by 24
Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy
Schneider, A.-F. E., & Aartsma-Rus, A. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1832462 · Cited by 25
The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter
Gollavilli, P. N., Parma, B., Siddiqui, A., Yang, H., Ramesh, V., Napoli, F., Schwab, A., Natesan, R., Mielenz, D., Asangani, I. A., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01708-6 · Cited by 24
Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art
Barbullushi, K., Abati, E., Rizzo, F., Bresolin, N., Comi, G. P., & Corti, S. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1533-2 · Cited by 23
Combined gene essentiality scoring improves the prediction of cancer dependency maps
Wang, W., Malyutina, A., Pessia, A., Saarela, J., Heckman, C. A., & Tang, J. P. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.051 · Cited by 23
Applications of CRISPR‐Cas9 in gynecological cancer research
Zhang, W., Liu, Y., Zhou, X., Zhao, R., & Wang, H. (2020) · Clinical Genetics · doi:10.1111/cge.13717 · Cited by 23
Targeted Delivery of CRISPR/Cas13 as a Promising Therapeutic Approach to Treat SARS-CoV-2
Abbaszadeh‐Goudarzi, K., Nematollahi, M. H., Khanbabaei, H., Hosseini-Nave, H., Mirzaei, H. R., Pourghadamyari, H., & Sahebkar, A. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666201009154517 · Cited by 24
Biologia futura: animal testing in drug development—the past, the present and the future
Sántha, M. (2020) · Biologia Futura · doi:10.1007/s42977-020-00050-4 · Cited by 23
Modification of Cas9, gRNA and PAM: Key to further regulate genome editing and its applications
Gupta, R. K., Gupta, D., Kazi, T. A., Dey, D., Singh, R., Swarnakar, S., Ravichandiran, V., Roy, S., & Ghosh, D. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.001 · Cited by 23
Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis
Wen, J., Cao, T., Wu, J., Chen, Y., Zhi, S., Huang, Y., Zhen, P., Wu, G., Aagaard, L., Zhong, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.010 · Cited by 24

Authors: Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H.
Affiliations: McGovern Institute for Brain Research (US)
ORCID: Tee, Louis Y
Venue: Molecular Therapy - Nucleic Acids
Publisher: Elsevier BV
Published: 2015
Volume: 4
Pages: e264
ISSN: 2162-2531 (ISSN-L)
DOI: 10.1038/mtna.2015.37
PMC: PMC4877446
OpenAlex: W2173737475
Cited by: 1,273
References: 82
Citations by year: 2026: 67 · 2025: 145 · 2024: 166 · 2023: 151 · 2022: 164 · 2021: 198 · 2020: 132 · 2019: 109 · 2018: 80 · 2017: 35 · 2016: 25 · 2015: 1
FWCI: 4.55
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-sa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-sa/4.0/ (vor, 645 d)
Locations: Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-sa)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: CRISPR/Cas9, off-target effects, genome editing, RNA-guided endonuclease, genome editing specificity, therapeutic genome editing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks